HK Stock Movement | SHANDONG XINHUA (00719) Rises Over 4% as Lidocaine and Prilocaine Cream Gains Approval

Stock News11-25

SHANDONG XINHUA (00719) surged more than 4%, reaching HK$7.05 by the time of writing, with a trading volume of HK$19.36 million. The rally follows the latest announcement from China's National Medical Products Administration (NMPA) on November 24, approving the market launch of the company's Lidocaine and Prilocaine Cream under the registration category 4, which is considered equivalent to passing evaluation.

Lidocaine and Prilocaine Cream is a compound formulation of lidocaine and prilocaine, primarily used for local anesthesia on intact skin and as a pretreatment for superficial surgical procedures on genital mucosa. Compared to traditional anesthetics, it offers advantages such as convenience, higher safety, and non-dependency.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171070265?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171070265","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | SHANDONG XINHUA (00719) Rises Over 4% as Lidocaine and Prilocaine Cream Gains Approval","media":"Stock News","content":"<p>SHANDONG XINHUA (00719) surged more than 4%, reaching HK$7.05 by the time of writing, with a trading volume of HK$19.36 million. The rally follows the latest announcement from China's National Medical Products Administration (NMPA) on November 24, approving the market launch of the company's Lidocaine and Prilocaine Cream under the registration category 4, which is considered equivalent to passing evaluation.</p>\n<p>Lidocaine and Prilocaine Cream is a compound formulation of lidocaine and prilocaine, primarily used for local anesthesia on intact skin and as a pretreatment for superficial surgical procedures on genital mucosa. Compared to traditional anesthetics, it offers advantages such as convenience, higher safety, and non-dependency.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | SHANDONG XINHUA (00719) Rises Over 4% as Lidocaine and Prilocaine Cream Gains Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | SHANDONG XINHUA (00719) Rises Over 4% as Lidocaine and Prilocaine Cream Gains Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-25 11:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANDONG XINHUA (00719) surged more than 4%, reaching HK$7.05 by the time of writing, with a trading volume of HK$19.36 million. The rally follows the latest announcement from China's National Medical Products Administration (NMPA) on November 24, approving the market launch of the company's Lidocaine and Prilocaine Cream under the registration category 4, which is considered equivalent to passing evaluation.</p>\n<p>Lidocaine and Prilocaine Cream is a compound formulation of lidocaine and prilocaine, primarily used for local anesthesia on intact skin and as a pretreatment for superficial surgical procedures on genital mucosa. Compared to traditional anesthetics, it offers advantages such as convenience, higher safety, and non-dependency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1171070265","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171070265","pubTimestamp":1764040932,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SHANDONG XINHUA (00719) surged more than 4%, reaching HK$7.05 by the time of writing, with a trading volume of HK$19.36 million. The rally follows the latest announcement from China's National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","00719":"山东新华制药股份","BK1515":"抗疫概念"},"translate_title":"港股动向|利多卡因丙胺卡因乳膏获批山东新华(00719)涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"SHANDONG XINHUA (00719) surged more than 4%, reaching HK$7.05 by the time of writing, with a trading volume of HK$19.36 million. The rally follows the latest announcement from China's National Medical Products Administration (NMPA) on November 24, approving the market launch of the company's Lidocaine and Prilocaine Cream under the registration category 4, which is considered equivalent to passing evaluation.\nLidocaine and Prilocaine Cream is a compound formulation of lidocaine and prilocaine, primarily used for local anesthesia on intact skin and as a pretreatment for superficial surgical procedures on genital mucosa. Compared to traditional anesthetics, it offers advantages such as convenience, higher safety, and non-dependency.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171070265","isCrawlerRequest":true}